Probal Banerjee | Biological Network | Best Researcher Award

Published on by Network Science

Dr. Probal Banerjee | Biological Network | Best Researcher Award

The College of Staten Island (City University of New York) | United States

Dr. Probal Banerjee is a distinguished biochemist and neuroscientist whose academic and research career spans over four decades of excellence in bioorganic chemistry, molecular neuroscience, and cancer research. He earned his B.Sc. in Chemistry (Hons) and M.Sc. in Organic Chemistry from Jadavpur University, Calcutta, followed by a Ph.D. in Bioorganic Chemistry from the Indian Institute of Science, Bangalore in 1984. He completed postdoctoral research at the University of Notre Dame in Biochemistry and Enzymology and at the University of Chicago in Molecular Neuroscience. Currently a Professor of Chemistry and Coordinator at the Center for Developmental Neuroscience, College of Staten Island, CUNY, Dr. Banerjee has made pioneering contributions to understanding neurodevelopmental signaling and immune-modulating cancer therapies. His numerous honors include the Children’s Research Foundation Grant (1989), Brain Research Foundation Award, and two Dolphin Awards for Academic Excellence and Teaching. A sought-after speaker, he has delivered invited lectures at leading institutions worldwide on topics ranging from serotonin signaling in brain development to multi-target cancer therapeutics. Dr. Banerjee is also an inventor with several patents on curcumin-based anticancer agents and therapeutic approaches for Fragile X Syndrome. His expertise is widely recognized through his service on multiple NIH grant review committees, reflecting his enduring impact on neuroscience, pharmacology, and translational cancer research.

Profiles: Orcid 

Featured Publications

"Novel Taxol-Derivative, STO-1, Induces Selective Anti-Tumor Immunity and Sustained Remission of Glioblastoma Without Triggering Autoimmune Reactions", Shubhasmita Mohapatra; Adrian Guerrero; Neha Rahman; Khondoker Takia Zaman; Jing Wu; Callistus Onyeagba; Chanyue Hu; Matteo Pellegrini; Jayaram Vankudoth; Seiya Kitamura et al., Cells, 2025.

"One-Pot Synthesis of Phenylboronic Acid-Based Microgels for Tunable Gate of Glucose-Responsive Insulin Release at Physiological pH", Prashun G. Roy; Jiangtao Zhang; Koushik Bhattacharya; Probal Banerjee; Jing Shen; Shuiqin Zhou, Molecules, 2025.

"Biocompatible Anisole-Nonlinear PEG Core–Shell Nanogels for High Loading Capacity, Excellent Stability, and Controlled Release of Curcumin", Jing Shen; Jiangtao Zhang; Weitai Wu; Probal Banerjee; Shuiqin Zhou, Gels 2023.

"The G Protein-Coupled Serotonin 1A Receptor Augments Protein Kinase Cε-Mediated Neurogenesis in Neonatal Mouse Hippocampus-PKCε-Mediated Signaling in the Early Hippocampus", Sreyashi Samaddar; Sudarshana Purkayastha; Souleymane Diallo; Subramanyam J. Tantry; Ryan Schroder; Pranavan Chanthrakumar; Michael J. Flory; Probal Banerjee, International Journal of Molecular Sciences 2022.

"Phytosomal curcumin causes natural killer cell-dependent repolarization of glioblastoma (GBM) tumor-associated microglia/macrophages and elimination of GBM and GBM stem cells", Sumit Mukherjee; Angela Fried; Rahman Hussaini; Richard White; Juliet Baidoo; Sri Yalamanchi; Probal Banerjee, Journal of Experimental & Clinical Cancer Research, 2018.

Nikhil Sudhir Sathe | Biological Networks | Best Researcher Award

Published on by Network Science

Dr. Nikhil Sudhir Sathe | Biological Networks | Best Researcher Award

Reliance Life Sciences Pvt Ltd | India

Dr. Nikhil Sudhir Sathe (PhD), currently associated with Laboratory Animal Research Services (LARS), is a distinguished researcher with over 20 years of expertise in drug discovery and preclinical evaluation of new chemical entities. His extensive professional experience encompasses in vitro genotoxicology, cell and microbial culture (aerobic, anaerobic, and viral systems including rabies virus), and small laboratory animal studies. Throughout his career at Reliance Life Sciences, Vimta Labs, Dabur Research Centre, and Wockhardt Research Centre, Dr. Sathe has demonstrated exceptional proficiency in GLP-compliant laboratory practices, including bacterial reverse mutation, chromosomal aberration, micronucleus, ELISA, cytotoxicity, and microbial monitoring assays. His early research contributions involved innovative in vitro models for evaluating the efficacy of antimicrobial and cosmetic products. Academically, he holds a Master’s and Bachelor’s degree in Microbiology from Shivaji University, Kolhapur, both with distinction. Dr. Sathe has contributed significantly to scientific literature with publications in reputed journals such as Vaccine, Microbial Pathogenesis, Infectious Medicine, and BioMed, focusing on bacteriophage therapy and vaccine development against multidrug-resistant pathogens and SARS-CoV-2. His scholarly achievements are complemented by active participation in national conferences and workshops, reflecting his deep commitment to advancing microbiological and biomedical research.

Profiles: Scopus | Orcid | Google Scholar

Featured Publications

"Unveiling Lytic Bacteriophages as Promising Biotherapeutics for the Control of Multidrug-Resistant Pseudomonas aeruginosa", CS Nikhil Sathe, Eugene Athan, Arnab Kapat, BioMed, 2025.

"Safety, immunogenicity and efficacy of Relcovax®, a dual receptor binding domain (RBD) and nucleocapsid (N) subunit protein vaccine candidate against SARS-CoV-2 virus", N Sathe, S Shaikh, M Bhavsar, L Parte, A Gadiparthi, S Kad, S Sensarma, Vaccine, 2024.

"Bacteriophage vB_kpnS-Kpn15: Unveiling its potential triumph against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae-Unraveling efficacy through innovative", N Sathe, C Suphioglu, E Athan, A Kapat, Microbial Pathogenesis, 2024.

"Pseudomonas aeruginosa: Infections and novel approaches to treatment “Knowing the enemy” the threat of Pseudomonas aeruginosa and exploring novel approaches to treatment", N Sathe, P Beech, L Croft, C Suphioglu, A Kapat, E Athan, Infectious medicine 2, 2023.

"Development of a novel therapy using bacteriophages: An alternative to antibiotics", NS Sathe, Deakin University, 2023.

Anna Maria Pittaluga | Biological Networks | Top Researcher Award

Published on by Network Science

Prof. Anna Maria Pittaluga | Biological Networks | Top Researcher Award

University of Genoa | Italy

Anna Maria Pittaluga is a distinguished pharmacologist with a PhD in Pharmacology and Toxicology from the University of Turin (1990), and MSc degrees in Pharmacy (1983) and in Pharmaceutical Chemistry and Technology with honors (1982) from the University of Genova. She has built a long-standing academic career at the University of Genoa, where she has served as Assistant Professor (1993–2003), Associate Professor (2004–2019), and currently as Full Professor of Pharmacology since 2019. Earlier in her career, she gained international research experience as a Research Fellow at the Italian National Research Council (1990–1992) and as a Foreign Research Associate at Collège de France in Paris (1988–1989). Her scientific interests focus on neurotransmitter release mechanisms, receptor interactions, the effects of HIV-1 proteins and chemokines on central neurotransmission, synaptic function in multiple sclerosis, the neuro-immune interface, and the role of nutraceutics in brain health. She has led numerous national and international projects funded by the Italian Ministry of Research, Ministry of Health, and European programs, serving as principal investigator on studies addressing neuroinflammation, depression, synaptopathies, and the gut-brain axis. Proficient in English and French, in addition to her native Italian, Professor Pittaluga has made significant contributions to advancing pharmacological research with strong translational and clinical implications.

Profiles: Scopus | Orcid | Google Scholar

Featured Publications

"Correction: Vallarino et al. Healthy Properties of a New Formulation of Pomegranate-Peel Extract in Mice Suffering from Experimental Autoimmune Encephalomyelitis"

"Unveiling Niaprazine’s Potential: Behavioral Insights into a Re-Emerging Anxiolytic Agent"

"Complement tunes glutamate release and supports synaptic impairments in an animal model of multiple sclerosis"

"Anti-NMDA and Anti-AMPA Receptor Antibodies in Central Disorders: Preclinical Approaches to Assess Their Pathological Role and Translatability to Clinic"

"Presynaptic Release-Regulating Sphingosine 1-Phosphate 1/3 Receptors in Cortical Glutamatergic Terminals: Adaptations in EAE Mice and Impact of Therapeutic FTY720"

Tamar Kinaciyan | Medicine | Best Research Article Award

Published on by Network Science

Dr. Tamar Kinaciyan | Medicine | Best Research Article Award

Department of Dermatotolgy, Medical University of Vienna | Austria

Author Profile

Scopus

Orcid ID

Early Academic Pursuits

Dr. Tamar Kinaciyan embarked on her medical and dermatological journey at the Medical University of Vienna, where she completed her dermatology board examination in 1996 and specialized in environmental medicine and clinical allergology. Her early academic roles included heading the Borrelia-Outpatient Clinic (1994–2000) and directing immune fluorescence microscopy and antigen-mapping laboratories for bullous and connective tissue diseases (1993–1998). She further strengthened her clinical research foundation through diplomas in dermatoscopy, clinical investigation, and lung function analysis, laying a solid groundwork for her career in pediatric dermatology and allergology.

Professional Endeavors

Dr. Kinaciyan’s professional trajectory spans nearly three decades, marked by leadership roles in both clinical and organizational settings. She serves as Head of the Allergy and Pediatric Dermatology Clinics at the Department of Dermatology, Medical University of Vienna, and leads multiple specialized centers, including ACARE, HAE, and UCARE. Her contributions extend to international collaboration through Ga2LEN ACARE Centers and to advocacy for women in science as founder and honorary president of the Women’s Science Network Medicine. She has also held numerous key roles in Austrian and European scientific societies, reflecting her commitment to both clinical excellence and professional mentorship.

Contributions and Research Focus

Dr. Kinaciyan’s research primarily focuses on hereditary angioedema, urticaria, mastocytosis, and pediatric dermatology, alongside investigations into food allergies, latex allergy, drug hypersensitivity, and eczema. She has led and participated in multiple clinical trials, EU projects, and Austrian national studies, including the Austrian Registry of Bradykinin-mediated Angioedema and studies on sublingual immunotherapy for birch pollen-related food allergies. Her work bridges clinical and translational research, advancing diagnostic and therapeutic approaches for rare and complex allergic and dermatologic conditions.

Impact and Influence

Her clinical and research expertise has significantly influenced European and global dermatology and allergology communities. Dr. Kinaciyan has chaired numerous congress sessions, contributed to guideline task forces, and served as an editorial board member for several high-impact journals, including the Journal of Exploration of Asthma & Allergy. Her mentorship and advocacy efforts, particularly through WNW-med, have empowered foreign-trained physicians and supported gender equity in medical sciences, establishing her as both a thought leader and a mentor.

Academic Citations

Dr. Kinaciyan has a strong publication record with 88 peer-reviewed, Medline-indexed articles, totaling an impact factor of 782.704 and an h-index of 28. Her contributions span original research, invited articles, book chapters, and case studies in prestigious journals and texts, reflecting her broad influence across allergology and dermatology.

Legacy and Future Contributions

Dr. Kinaciyan’s legacy lies in her dual commitment to advancing clinical dermatology and fostering the next generation of medical researchers. By integrating cutting-edge research with patient-centered care and promoting inclusive academic networks, she has set a standard for excellence in both practice and mentorship. Moving forward, her continued focus on hereditary angioedema, pediatric dermatology, and clinical allergology promises to deepen scientific understanding and improve patient outcomes globally.

Conclusion

Dr. Tamar Kinaciyan exemplifies a rare combination of clinical acumen, research innovation, and leadership. Her pioneering work in hereditary angioedema and pediatric dermatology, coupled with her dedication to professional development and mentorship, has left an indelible mark on the field. With a prolific publication record, numerous awards, and sustained international impact, she stands as a leading figure whose ongoing contributions continue to advance both science and patient care.

Notable Publications

“Diagnostic difficulties in pediatric annular dermatoses" 

  • Author: Doris Weiss; Philipp Weber; Amélie Hampel; Julia Tittes; Wolfgang Weninger; Tamar Kinaciyan
  • Journal: Wiener Medizinische Wochenschrift
  • Year: 2024

“The Chronic Angioedema Registry (CARE): Rationale, Methods and Implementation" 

  • Author: Buttgereit T; Aulenbacher F; Gutsche A; Kolkhir P; Weller K; Vera Ayala C; Magerl M; Farkas H; Grumach AS; Aygören-Pürsün E et al.
  • Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • Year: 2024

“Docetaxel‐induced symmetrical drug‐related intertriginous and flexural exanthema (SDRIFE) confirmed by skin testing" 

  • Author: Amélie Hampel; Tamar Kinaciyan
  • Journal: Contact Dermatitis
  • Year: 2024

“Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus" 

  • Author: Reshef A; Buttgereit T; Betschel SD; Caballero T; Farkas H; Grumach AS; Hide M; Jindal AK; Longhurst H; Peter J et al.
  • Journal: The Journal of allergy and clinical immunology
  • Year: 2024

“The changing epidemiology of human leishmaniasis in the non-endemic country of Austria between 2000 to 2021, including a congenital case." 

  • Author: Riebenbauer K; Czerny S; Egg M; Urban N; Kinaciyan T; Hampel A; Fidelsberger L; Karlhofer F; Porkert S; Walochnik J et al.
  • Journal: PLoS neglected tropical diseases
  • Year: 2024

 

 

 

Dmitry Guschin | Biological Networks |  Outstanding Research Achievement Award

Published on by Network Science

Dr. Dmitry Guschin | Biological Networks |  Outstanding Research Achievement Award

Sirius university of Science and Technology | Russia

Author Profiles

Oricd ID

Google Scholar

Early Academic Pursuits

Dr. Dmitry Guschin began his scientific journey in Moscow, Russia, where his early research as a Research Scientist at the Laboratory of Chromosome Structure (1990–1991) focused on the role of histone tails in maintaining chromatin structure during transcription. This pioneering work, published in Cell, laid the foundation for his long-term interest in chromatin dynamics and molecular mechanisms of gene regulation. His subsequent fellowship at the Imperial Cancer Research Fund in London (1991–1995) enabled him to uncover the role of Jak kinases in interferon signaling, a finding published in Nature. These formative years established his reputation as a molecular biologist with a keen ability to address fundamental questions in gene regulation.

Professional Endeavors

Throughout his career, Dr. Guschin has held prestigious positions across internationally recognized institutions. From visiting scientist roles at Argonne National Laboratory and the NIH, to his decade-long tenure at Sangamo BioSciences (2000–2014), he contributed to groundbreaking advances in genome editing. His later positions at the Institute of Basic Science in Korea (2015–2019), Moscow Institute of Physics and Technology (2019–2022), Ecole Polytechnique (2021), Nazarbaev University (2023–2024), and his current role as Lead Scientist at Sirius University (2024–) reflect a global career marked by innovation, collaboration, and leadership.

Contributions and Research Focus

Dr. Guschin’s research has consistently revolved around genome editing, chromatin biology, and translational medicine. At Sangamo BioSciences, he demonstrated targeted deletions using Zinc-Finger nucleases and developed methods for genome mutation detection, securing 10 U.S. patents. His contributions to CRISPR research at the Institute of Basic Science in Korea, where he engineered Cpf1 (CRISPR type V) proteins with novel PAM specificities, further advanced gene-editing precision. Additionally, his innovations in base editing and co-selection strategies positioned him as a thought leader in functional genomics.

Impact and Influence

The global trajectory of Dr. Guschin’s career underscores his broad scientific influence. His work has impacted both fundamental science-such as uncovering chromatin regulation mechanisms-and applied biotechnology, including methods adopted for therapeutic genome editing. His publications in Cell, Nature, Nature Biotechnology, and Science highlight the international recognition of his discoveries. Moreover, his patents and translational research contributions demonstrate lasting influence on both academia and industry.

Academic Citations

With over 20 peer-reviewed publications in top-tier journals, Dr. Guschin’s scholarship has been widely cited across molecular biology, biochemistry, and genome engineering fields. His publications not only advanced scientific discourse but also served as reference points for subsequent innovations in gene-editing technologies and cancer research.

Legacy and Future Contributions

Dr. Guschin’s legacy lies in bridging basic molecular discoveries with applied genome-editing technologies. His early contributions to chromatin biology and interferon signaling remain benchmarks in molecular biology, while his later work in Zinc-Finger nucleases and CRISPR engineering has influenced therapeutic development pipelines. In his current role at Sirius University, he continues to shape translational medicine by focusing on colloidal medicine and advanced biomedical applications. Looking forward, his expertise positions him to mentor future scientists and contribute to cutting-edge therapies in personalized medicine.

Conclusion

Dr. Dmitry Guschin’s career reflects a rare blend of scientific depth, technological innovation, and translational impact. From uncovering fundamental molecular mechanisms to pioneering genome-editing tools and mentoring the next generation, his contributions have left an indelible mark on modern biology. His ongoing work promises to expand the horizons of translational and personalized medicine, ensuring his influence will continue to grow in both academic and clinical domains.

Notable Publications

"Circulating Tumor DNA in Prostate Cancer: A Dual Perspective on Early Detection and Advanced Disease Management" 

  • Author: Stepan A. Kopytov; Guzel R. Sagitova; Dmitry Y. Guschin; Vera S. Egorova; Andrei V. Zvyagin; Alexey S. Rzhevskiy
  • Journal: Cancers
  • Year: 2025

"Modern approaches to engineering human reporter cell lines using CRISPR within Safe Harbor loci and endogenous genes" 

  • Author: A. G. Bykonya; D. Y. Guschin; N. A. Barlev
  • Journal: Critical Reviews in Biotechnology
  • Year: 2025

"Vinculin–Arp2/3 interaction inhibits branched actin assembly to control migration and proliferation" 

  • Author: John James; Artem I Fokin; Dmitry Y Guschin; Hong Wang; Anna Polesskaya; Svetlana N Rubtsova; Christophe Le Clainche; Pascal Silberzan; Alexis M Gautreau; Stéphane Romero
  • Journal: Life Science Alliance
  • Year: 2025

"BRCA Mutations-The Achilles Heel of Breast, Ovarian and Other Epithelial Cancers" 

  • Author: Loboda, Anna P.; Adonin, Leonid S.; Zvereva, Svetlana D.; Guschin, Dmitri Y.; Korneenko, Tatyana V.; Telegina, Alexandra V.; Kondratieva, Olga K.; Frolova, Sofia E.; Pestov, Nikolay B.; Barlev, Nick A.
  • Journal: International Journal of Molecular Sciences
  • Year: 2023

"Vinculin-Arp2/3 Interaction Inhibits Branched Actin Assembly to Control Cell Migration and Cell Cycle Progression" 

  • Author: John James; Artem I. Fokin; Dmitry Y. Guschin; Hong Wang; Anna Polesskaya; Svetlana N. Rubtsova; Christophe Le Clainche; Pascal Silberzan; Alexis M. Gautreau; Stéphane Romero
  • Journal: Preprint
  • Year: 2023

 

 

Zhengyang Guo | Metabolism Networks | Best Researcher Award

Published on by Network Science

Dr. Zhengyang Guo | Metabolism Networks | Best Researcher Award

Peking University Third Hospital | China

Author Profile 

Scopus

Early Academic Pursuits

Zhengyang Guo’s academic journey began with a strong foundation in the life sciences. He earned his Bachelor’s degree from the School of Basic Medical Sciences at Peking University, which provided him with comprehensive knowledge in biomedical sciences. His pursuit of higher education continued at the Department of Microbiology, Peking University, where he obtained his M.D. degree. This academic background not only reflects his commitment to advancing medical research but also highlights the interdisciplinary foundation that shaped his later contributions in oncology and immunology.

Professional Endeavors

Currently serving as an Assistant Professor at Peking University Third Hospital, Guo has dedicated his professional career to the study of tumor biology and clinical translational research. Alongside his teaching responsibilities, he actively contributes to developing cutting-edge techniques through his involvement in the immunology platform and guiding graduate students in experimental teaching. His professional endeavors balance research, teaching, and technological development, underlining his role as both a researcher and mentor.

Contributions and Research Focus

Dr. Guo’s research primarily centers on tumor epigenetics, tumor metabolism, and the tumor microenvironment. His innovative work investigates molecular mechanisms that influence cancer progression and therapeutic outcomes. Specifically, he has focused on targeting the enzyme SCD1 in combination with EZH2 inhibitors to enhance the efficacy of melanoma treatment and immunotherapy. His projects, supported by prestigious funding bodies such as the National Natural Science Foundation of China and Peking University Medicine Fund, reflect both the clinical relevance and scientific novelty of his work.

Impact and Influence

As an active contributor to the global scientific community, Guo holds membership in the Biophysical Society of China and the Chinese Society of Biochemistry and Molecular Biology. His expertise is recognized internationally, as he serves as a peer reviewer for high-impact journals including Experimental Hematology & Oncology, Cell Communication and Signaling, Apoptosis, and Lipids in Health and Disease. These engagements highlight his influence in shaping scientific dialogue and advancing standards in cancer research.

Academic Cites and Intellectual Property

Guo’s research impact extends beyond publications into intellectual property and patents. He is a co-inventor on multiple patents related to antitumor drug compositions involving EZH2 and SCD1 inhibitors, as well as novel approaches to treating liver cancer using diacylglycerol kinase γ. These patents underscore the translational potential of his work, bridging basic molecular research with therapeutic innovation. His contributions are already shaping new pathways in drug discovery and cancer therapy.

Legacy and Future Contributions

With a strong foundation of academic excellence, innovative research, and translational breakthroughs, Guo is poised to make long-lasting contributions to the field of oncology. His ongoing efforts in epigenetic regulation, tumor metabolism, and immunotherapy strategies hold promise for redefining cancer treatment paradigms. By mentoring future scholars and fostering collaborations across disciplines, he is actively building a legacy that will continue to influence both academia and clinical practice.

Conclusion

In summary, Dr. Zhengyang Guo exemplifies the qualities of a modern medical researcher-a scholar who bridges fundamental biology with clinical application. His journey from early academic pursuits to groundbreaking research in tumor biology reflects dedication, innovation, and leadership. With multiple funded projects, patents, and international recognition, his work significantly impacts the scientific community and promises future advancements in cancer treatment. His career trajectory positions him as a leading figure in biomedical research, with the potential to transform cancer therapy at both national and global levels.

Notable Publications

"3G Internet Diffusion and Secondary Education Attainment: Evidence of Opportunity Cost in Vietnam" 

  • Author: Trang Thi Pham; Bernardo Caldarola
  • Journal: Review of Development Economics
  • Year: 2025